Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception

Ahn, Dong K.a,*,1; Choi, Hyo S.a,1; Yeo, Sang P.a; Woo, Young W.a; Lee, Min K.a; Yang, Gwi Y.a; Jeon, Hye J.a; Park, Jae S.b; Mokha, Sukhbir S.c

doi: 10.1016/j.pain.2007.01.015
Research papers

The present study is the first to investigate the participation of central cyclooxygenase (COX) pathways in modulating the antinociceptive effects of intracisternally administered cannabinoid on nociception induced by inflammation of the temporomandibular joint (TMJ) in freely moving rats. Following intra-articular injection of 5% formalin in the TMJ, nociceptive scratching behavior was recorded for nine successive 5-min intervals in Sprague–Dawley rats. Intracisternal injection of 30 μg of WIN 55,212-2, a synthetic non-subtype-selective CB1/2 agonist, administered 20 min prior to formalin injection significantly reduced the number of scratches and duration of scratching induced by formalin compared with the vehicle-treated group. Antinociceptive effect of WIN 55,212-2 was blocked by intracisternal injection of 10 μg of AM251, a CB1 receptor-selective antagonist, but not by AM630, a CB2 receptor-selective antagonist. A 10 μg dose of WIN 55,212-2 that was ineffective in producing antinociception became effective following intracisternal administration of NS-398, a selective COX-2 inhibitor; indomethacin, a non-selective COX 1/2 inhibitor; acetaminophen, a putative COX-3 inhibitor, but not following pretreatment with the selective COX-1 inhibitor, SC-560. The ED50 value of WIN 55,212-2 in the NS-398-treated group was significantly lower than that in the vehicle-treated group. Importantly, administration of low doses of COX inhibitors alone did not attenuate nociception. These results indicate that inhibition of central COX pathways, presumably via COX-2 inhibition, reduces inflammatory pain by enhancing the cannabinoid-induced antinociceptive effect. Based on our observations, combined administration of cannabinoids with COX inhibitors may hold a therapeutic promise in the treatment of inflammatory TMJ pain.

aDepartment of Oral Physiology and BrainKorea21, School of Dentistry, Kyungpook National University, Daegu, Republic of Korea

bDepartment of Physiology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

cDivision of Neurobiology and Neurotoxicology, Meharry Medical College, 1005 D.B. Todd Blvd., Nashville, TN 37208, USA

*Corresponding author. Tel.: +82 53 660 6840; fax: +82 53 421 4077.



1These authors contributed equally to this paper.



Submitted July 14, 2006; received in revised form December 21, 2006; accepted January 10, 2007.

© 2007 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website